Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
The structure was published by Sutherlin, D.P., Sampath, D., Berry, M., et al., Wiesmann, C., Wong, S., and Zhu, B.Y., in 2010 in a paper entitled "Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer." (abstract).
This crystal structure was determined using X-ray diffraction at a resolution of 3.0 Å and deposited in 2009.
The experimental data on which the structure is based was also deposited.
The PDB entry contains the structure of Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform. This molecule has the UniProt identifier P48736 (PK3CG_HUMAN). The sample contained 966 residues which is < 90% of the natural sequence. Out of 966 residues 841 were observed and are deposited in the PDB.
It also contains one or more heterogenic compounds (e.g., ligands, co-factors, ions, modified amino acids, etc.); see here for a complete list.
The molecule is most likely monomeric.
The following tables show cross-reference information to other databases (to obtain a list of all PDB entries sharing the same property or classification, click on the magnifying glass icon):
This entry contains 1 unique UniProt protein: